This was the stock's second consecutive day of losses.

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies ...

Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company ...

Valeo Financial Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Edwards Lifesciences Corp. closed 21.12% short of its 52-week high of $96.12, which the company reached on March 28th.

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...